04:55am Tuesday 17 October 2017

Antiplatelets: 1 person, 1 dose?

Montreal – An international consortium of scientists, including major contributions from the Montreal Heart Institute, demonstrates that the “one-size fits all” strategy of uniformly doubling the dose of an antiplatelet drug, clopidogrel, for patients with high on-treatment platelet reactivity does not reduce the incidence on death, heart attacks and stent thrombosis after percutaneous coronary intervention (PCI). The results of the GRAVITAS trial conducted to determine whether high-dose clopidogrel is superior to standard-dose therapy for the prevention of cardiovascular events after percutaneous coronary intervention in patients with high on-treatment reactivity, have been published recently in the Journal of the American Medical Association.

The GRAVITAS (Gauging Responsiveness with A VerifyNow assay – Impact on Thrombosis And Safety) study showed no benefit of double-dose compared with standard-dose clopidogrel and the results refute the strategy of uniformly doubling the dose of clopidogrel over six months for patients with high on-treatment platelet reactivity after PCI with drug-eluting stent. In the multicenter, randomized, double-blind, active-control trial, the use of high-dose compared with standard-dose clopidogrel did not reduce the incidence of adverse cardiac events such as death, nonfatal myocardial infarction or stent thrombosis.

“The results of GRAVITAS are surprising because they do not support a uniform treatment strategy of high-dose clopidogrel in patients with high on-treatment reactivity.” said Dr. Jean-François Tanguay, interventional cardiologist at the Montreal Heart Institute, professor of medicine at the Université de Montréal and lead investigator in Canada. “Personalized medicine merits further investigation. We need to assess alternative treatment strategies incorporating platelet function testing as opposed to prescribe a fixed, higher dose.”

Between July 2008 and April 2010, 2214 patients from 83 sites in North America had high on-treatment reactivity after being screened with platelet function testing 12 to 24 hours after PCI. They were randomly assigned to either higher (double-dose) or standard-dose clopidogrel for six months after drug-eluting stent implantation. An additional 586 patients without high on-treatment reactivity were selected at random and assigned to treatment with standard-dose clopidogrel. Clopidogrel exposure prior to enrollment was similar across all 3 treatment groups.

At six months, the rate of death from cardiovascular causes, nonfatal myocardial infarction or stent thrombosis was not different with high-dose (25 of 1109 patients) compared with standard-dose (25 of 1105 patients) clopidogrel in patients with high on-treatment reactivity. ”These low event rates reflect the excellent results we can obtain with drug-eluting stents” said Dr. Tanguay.

###

About antiplatelets:

Antiplatelets (such as aspirin, clopidogrel, prasugrel and dipyridamole) prevent platelet aggregation by making blood platelets less likely to stick together. Sticky platelets, which are common in damaged blood vessels, may form a blood clot and lead to a stroke or heart attack. Platelets are specialized cells in the blood that initiate a healing process. Antiplatelets are effective in the arterial circulation, where anticoagulants have little effect. They are widely used in primary and secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

About the Montreal Heart Institute: www.icm-mhi.org.

About GRAVITAS:

1: Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
JAMA, 2011 Mar 16;305(11):1097-105. PMID: 21406654

2: Gurbel PA, Tantry US.
An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial.
JAMA. 2011 Mar 16;305(11):1136-7. PMID: 21406654

Information: Julie Chevrette
Communications Officer
Montreal Heart Institute
514 376-3330, ext. 2641
julie.chevrette@icm-mhi.org

Contact: Julie Chevrette
julie.chevrette@icm-mhi.org
514-376-3330 x2641
Montreal Heart Institute 


Share on:
or:

MORE FROM Blood, Heart and Circulation

Health news